June 08, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.
Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA placed diphenidine, a synthetic opioid with similar effects to fentanyl, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA temporarily placed 2-Fluorodeschloroketamine in Schedule I, potentially impacting research and clinical use should this substance be considered alongside or as an alternative to cannabis-based treatments.
Read more →Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA placed cumyl-pegaclone, a synthetic cannabinoid, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the United States.
Read more →The DEA placed four synthetic cannabinoids into Schedule I, classifying them as having a high potential for abuse and no accepted medical use, impacting clinicians encountering patients using these substances.
Read more →The DEA proposes rescheduling FDA-approved products containing marijuana from Schedule I to Schedule III, potentially easing access for clinicians and patients while maintaining federal control.
Read more →Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
The DEA placed the synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting its legality and clinical research.
Read more →The DEA placed 3-Methoxyphencyclidine (3-MeO-PCP) into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting clinicians encountering similar substances.
Read more →Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
The DEA temporarily placed bromazolam, a benzodiazepine sometimes found in unregulated cannabis products, into Schedule I, making it illegal and impacting patient safety and clinician practices.
Read more →The DEA placed five benzodiazepines—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—into Schedule I, impacting clinicians who may encounter patients using these substances alongside cannabis.
Read more →Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA temporarily placed 2-Fluorodeschloroketamine in Schedule I, potentially impacting research and clinical use should this substance be considered as an adjunct therapy alongside cannabis.
Read more →Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I
This action places 4-fluoroamphetamine in Schedule I, meaning it has a high potential for abuse and no currently accepted medical use, which may impact research involving similar compounds or patient reporting of substance use.
Read more →The DEA placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, meaning these synthetic opioids have no accepted medical use and high abuse potential, potentially impacting differential diagnoses for cannabis patients presenting with altered mental states.
Read more →The DEA placed N-desethyl isotonitazene and N-piperidinyl etonitazene into Schedule I, impacting clinicians by restricting their use and potentially affecting patient testing due to cross-reactivity with fentanyl test strips.
Read more →The DEA placed four synthetic cannabinoids into Schedule I, classifying them as having a high potential for abuse and no accepted medical use, impacting clinicians encountering these substances in patient assessments.
Read more →Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I
The DEA temporarily placed bromazolam, a benzodiazepine sometimes found in unregulated cannabis products, into Schedule I, making it illegal and impacting patient safety and clinician practices.
Read more →Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA placed cumyl-pegaclone, a synthetic cannabinoid, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the United States.
Read more →Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I
The DEA placed 4-Chloromethcathinone in Schedule I, meaning it has a high potential for abuse and no currently accepted medical use, impacting clinicians assessing patient substance use.
Read more →The DEA temporarily placed six synthetic opioids into Schedule I, impacting cannabis clinicians and patients through potential cross-contamination of unregulated products and increased caution regarding substance identification.
Read more →Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I
The DEA placed the synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting its legality and clinical research.
Read more →This federal rule temporarily places seven fentanyl-related substances in Schedule I, potentially impacting access for research or clinical use should cannabis clinicians consider fentanyl analogs for pain management.
Read more →Digest-Level Clinical Commentary
Clinical Reflection on DEA Scheduling Actions Looking at this digest, I note that only item 5 directly addresses cannabis policy—the proposed rescheduling of FDA-approved cannabis products from Schedule I to Schedule III—while the remaining 19 items concern synthetic cannabinoids and other novel psychoactive substances, signaling the DEA’s continued focus on controlling designer drugs rather than reshaping cannabis regulation itself. This disconnect underscores that federal cannabis medicine practice remains constrained by Schedule I status despite growing clinical evidence for cannabinoid efficacy in specific conditions, meaning my ability to prescribe or recommend cannabis is still limited to states with medical cannabis laws, while the DEA expends considerable resources scheduling novel analogues that patients may turn to in cannabis’s absence. The regulatory landscape suggests a gradual, legalistic shift toward rescheduling cannabis-derived medications
The majority of these regulatory actions reflect the DEA’s ongoing efforts to control synthetic drugs of abuse that emerge faster than formal scheduling can accommodate them, including novel cannabinoids, benzodiazepines, opioids, and dissociatives. Item 5 stands out as the sole action addressing legitimate medical use, rescheduling FDA-approved cannabis products from Schedule I to Schedule III to align regulatory status with clinical reality. Clinicians should recognize that most of these placements represent public health responses to drugs with minimal therapeutic value and significant abuse potential, while remaining aware that rescheduling of cannabis preparations may gradually shift how some cannabinoid-based medications are regulated and prescribed.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it:
- Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
- Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
- Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
